ReviewBritish journal of haematology2025
Screening for monoclonal gammopathy of undetermined significance is contraindicated.
Review in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections.Cancer medicine · 2026Article
- Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.British journal of haematology · 2026Review
- Screening for monoclonal gammopathy of undetermined significance is contraindicated.British journal of haematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incidence of multiple myeloma is about 1.8/100 000. About 3%-5% of adults >50 years of age are diagnosed with monoclonal gammopathy of undetermined significance (MGUS). The prevalence is higher if diagnosis is based on an abnormal ratio of serum free light chains. 300-500 people/10 000 get labelled with a diagnosis of this pre-malignant disorder by using faulty criterion of abnormal light chain ratio. Diagnoses based on an abnormal light chain ratio are incorrect in 96% of instances. However, a large number of people are subjected to psychological trauma and financial toxicity by subjecting them to repeated and invasive testing. If strict criteria requiring the presence of a monoclonal immunoglobulin were used, only about 10 people/10 000 may have MGUS and only one person may progress to multiple myeloma in 10 years. Even that one person gains no benefit from an 'early' diagnosis. Thus, there is only harm and no benefit from screening for MGUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.